Research article · 6 Oct 2026
Review articlePublished 2015
Revisit Rescula and Cystoid Macular Edema and Refractory Glaucoma
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Rescula (unoprostone isopropyl) has been in the market as ocular hypotensive drug since 1994. There are amounting scientific research and post-marketing clinical experiences reported in peer review journals. Yet there seems limited understanding about its unique clinical implication associated with newly discovered molecular mechanism (traits) of BK channel activation. Hence this review article is using a focal lens with an eye on B-K channel activation to further delineate possible roles of rescula in modulating chronic parainflammation in the eye, which may eventually set it apart from the rest lipid hypotensive drugs such as latanoprost that is pro-inflammatory in nature. Cystoid macular edema and refractory glaucoma will be the key historical clinical case highlights.
Keywords
Subjects
Ophthalmology & OptometryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Experimental Ophthalmology.
Short communication · 30 Aug 2026
Vision Science in the Modern Era: Integrating Neuroscience, Genetics, and Technology
Commentary · 3 Aug 2026
Emerging Frontiers in Experimental Ophthalmology: Innovations and Translational Challenges
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Experimental Ophthalmology
- SubjectOphthalmology & Optometry
- BylineArticles whose byline prints “y Craven MD”
- BylineArticles whose byline prints “Martin W”
